Primary EP: [{"name":"Independence from IV calcium and active vitamin D at Week 26","type":"responder","results":[{"value":79,"arm_name":"TransCon PTH"},{"value":5,"arm_name":"Placebo"}]}]
Efficacy: Met primary: 79% vs 5% achieved independence from IV calcium and active vitamin D (p<0.0001). Published in peer-reviewed journal.
Notes
FDA approved Aug 12, 2024. First-ever hypoparathyroidism treatment. 2025 revenue €477M (preliminary). Q4 2025 alone was €187M. Transformational launch.